Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer
暂无分享,去创建一个
A. Tolcher | K. Papadopoulos | M. Beeram | A. Patnaik | L. Rosen | Xuekui Zhang | P. Kulanthaivel | J. Goldman | R. Bell | C. Pitou | A. Shahir | Peipei Shi | D. Farrington | E. Chan | A. Fink